Gastroparesis Treatment Insurance Denied? How to Appeal

Gastroparesis — a condition in which the stomach empties too slowly, causing chronic nausea, vomiting, bloating, and difficulty maintaining adequate nutrition — is a debilitating disorder that significantly impairs quality of life. Patients with gastroparesis frequently encounter insurance barriers, including denials for the gastric emptying scintigraphy study needed to confirm the diagnosis and for the gastric neurostimulator (Enterra device) that provides relief when medications fail. If your gastroparesis-related claim has been denied, understanding the insurer's reasoning and building a targeted appeal can make the difference between continued suffering and access to the care you need.

Why Insurers Deny Gastroparesis Treatment

Gastric emptying study denied for insufficient symptom documentation. Insurers require evidence of consistent gastroparesis symptoms before approving the diagnostic test. Clinical notes must document nausea, vomiting, early satiety, postprandial fullness, and upper abdominal discomfort — with duration and severity — for the test to be considered justified.

Mechanical obstruction not excluded. Most clinical guidelines and insurer policies require that structural causes of delayed gastric emptying — pyloric stenosis or an obstructing mass — have been excluded before gastric emptying scintigraphy is performed. An upper endoscopy or imaging study ruling out obstruction should be in the record.

Non-standard testing protocol. Some insurers deny gastric emptying studies because the test was not performed using the standardised four-hour nuclear medicine protocol recommended by the American Neurogastroenterology and Motility Society (ANMS) and the Society of Nuclear Medicine and Molecular Imaging. A shorter study or a non-standard meal triggers this basis for denial.

Prokinetic medication coverage disputes. Metoclopramide (Reglan) is the only FDA-approved prokinetic for gastroparesis; domperidone is commonly used internationally but lacks FDA approval in the US. Domperidone access requires special FDA authorisation through an Investigational New Drug (IND) application, and coverage disputes for this pathway are common.

Gastric neurostimulator (Enterra) denied as investigational. The Enterra Therapy gastric electrical stimulator is FDA-approved under a Humanitarian Device Exemption (HDE) — approved based on safety and probable benefit for a rare condition rather than the full efficacy standard applied to other devices. Insurers frequently classify the Enterra device as experimental or investigational, citing the HDE approval pathway as evidence of unproven efficacy.

Nutritional support coverage disputes. Enteral or parenteral nutrition may be denied when the insurer disputes the clinical necessity or fails to recognise gastroparesis as the qualifying diagnosis for tube feeding coverage.

How to Appeal a Gastroparesis Treatment Denial

Step 1: Identify the Specific Denial Basis

Determine whether the denial targets the diagnostic test, a prokinetic medication, the Enterra device, or nutritional support. Each requires a distinct evidentiary response. Obtain the denial letter and request the clinical policy bulletin the insurer used to evaluate your claim.

Step 2: Compile Complete Symptom Documentation

For gastric emptying study denials, your physician's clinical notes must document the presence, duration, and severity of nausea, vomiting, early satiety, and postprandial fullness. If notes are sparse, ask your gastroenterologist to write a detailed letter describing the full symptom history. Include records of prior upper endoscopy or imaging confirming the absence of mechanical obstruction.

Step 3: For Enterra Device Denials, Address the Investigational Classification Directly

Your appeal must confront the HDE investigational argument head-on. Clarify that the Enterra device received FDA approval through the Humanitarian Device Exemption pathway — a recognised FDA approval mechanism for devices treating rare conditions. Cite published clinical studies demonstrating reduction in hospitalisation rates and sustained improvement in nausea and vomiting for refractory gastroparesis patients. Reference the American College of Gastroenterology (ACG) and ANMS position statements acknowledging gastric electrical stimulation as an accepted treatment option for refractory gastroparesis. Document exhaustion of all prior treatment steps: dietary modification, all available prokinetic agents, antiemetics, and nutritional support where applicable.

Step 4: Document Treatment Failure for Each Prior Therapy

Insurance coverage of advanced gastroparesis treatment typically requires evidence that stepwise therapy has failed. Document dietary modification trials (small frequent meals, low-fat, low-fibre diet), each prokinetic agent prescribed with the duration of use and the reason for discontinuation or inadequate response, antiemetic regimens, and any hospitalisations for dehydration or nutritional deficiency.

erisa-appeal-rights">Step 5: Invoke ACA and ERISA Appeal Rights

Under the ACA (42 U.S.C. § 18001 et seq.) and 29 CFR § 2560.503-1, you have the right to an internal appeal and then an independent External Independent Review: Complete Guide" class="auto-link">external review if the internal appeal fails. Request that the external reviewer be a board-certified gastroenterologist specialising in motility disorders. External reviewers who apply ACG and ANMS guidelines rather than insurer-specific criteria frequently overturn denials for evidence-based gastroparesis treatment.

Step 6: Submit a Formal Written Appeal with Supporting Evidence

File your written appeal before the deadline stated in the denial letter (typically 180 days for commercial plans). Include all supporting evidence as labelled exhibits and address the insurer's denial reasons point by point.

What to Include in Your Appeal

• Clinical notes documenting nausea, vomiting, early satiety, and postprandial fullness with duration and severity
• Upper endoscopy or imaging report ruling out mechanical gastric obstruction
• Gastric emptying study report and nuclear medicine protocol confirmation
• Documentation of each failed prior treatment (prokinetics, antiemetics, dietary modification)
• Physician letter citing ACG or ANMS guidelines supporting the requested treatment for refractory gastroparesis

Fight Back With ClaimBack

Gastroparesis is a serious, under-recognised condition, and the insurance barriers patients face are well-documented. Whether your denial involves the diagnostic study, a prokinetic medication, or the Enterra device, a structured appeal citing ACG and ANMS guidelines and documenting treatment history gives you a strong foundation for reversal. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal